Moneycontrol
    Moneycontrol PRO
    LAMF
    LAMF

    Nifty Pharma

    Jump to

    • Divi's Labs, Lupin, other pharma stocks rise up to 4%; here's why HDFC Securities says sector looks 'attractive'

      Pharma stocks: India's share in global CRDMO market will likely rise to 4.7% by 2029 from 3.8% in 2024, making it an attractive sector, HDFC Securities said.

    • Pharma stocks jump up to 5% after US Senate passes Biosecure Act: Check top gainers

      Pharma stocks: The Biosecure Act bars some Chinese biotech companies from receiving federal funding.

    • Pharma index snaps four-day rally as Dr Reddy's, Biocon, other shares slide up to 2 percent: Factors at play

      Pharma stocks | 'With valuations moderating after recent corrections, selective accumulation in quality names could offer attractive returns once the broader sector stabilizes,' said market analyst Kalp Jain.

    • Pharma stocks fall up to 3% after Trump promises to significantly cut drug prices in US

      Pharma stocks: The Nifty Pharma index has now snapped a three-session gaining streak.

    • Pharma stocks slump as Trump shoots letters to 17 global drug majors seeking lower prices

      Trump's letters to 17 of the world’s biggest pharmaceutical majors has stated that companies should immediately lower charges for existing drugs, and furnish guarantee that future medicines be launched at par with what other countries are paying.

    • Pharma stocks in green even as Trump threatens 200% tariffs; Lupin, Biocon lead gains

      The pharma sector will be in focus on July 9, after Donald Trump said that he would make an announcement on pharmaceuticals tariffs soon.

    • Nifty Pharma sole sectoral gainer as investors await clarity on Trump tariffs; Ajanta Pharma, Ipca Labs lead gains

      Pharma stocks: The rise in the pharma stocks comes on the back of easing global trade tensions, with US President Donald Trump announcing that the trade deal between US and China is "done".

    • Dr Reddy's, Laurus Labs, other pharma stocks jump up to 3% amid bullish brokerage calls, other triggers

      The Nifty Pharma index is currently the top gaining sectoral index on NSE, rising over 1 percent to hover around 21,586.80.

    • Why generic pharma may dodge hit even as Trump revives drug pricing order

      Trump’s 'Most Favored Nation' policy could reignite legal battles; Indian generic makers seen insulated for now

    • Nifty Pharma recovers, Asian drugmakers shares tumble as Trump to slash US drug prices

      Indian pharmaceutical stocks recovered from their fall, after U.S. President Donald Trump announced a push to lower domestic drug prices between 30 to 80 percent.

    • Nifty Pharma crashes 3% as tariff fears spook investors; Biocon, IPCA Labs settle 6% lower

      Pharma stocks are trading in the red during the April 7 session, as tariff fears are reignited for the sector and investors cut their holdings.

    • Risk of high reciprocal tariffs on domestic pharma products is low, says CLSA

      CLSA said that even if tariffs are imposed, Indian drug makers are likely to pass on the costs, given their dominant market share.

    • Trump promises 'never-seen-before' pharma tariffs soon; Nifty Pharma cracks 4.5%, IPCA Labs, Lupin sink 6%

      Pharma stocks are trading in the red during the April 4 session, after a big rally in the previous session, as tariff fears are reignited for the sector.

    • Lupin, Dr Reddy's, other pharma stocks fall on Trump's 25% tariff plans

      Indian drugmakers earn a significant share of revenue from the US, the largest importer of Indian pharma products

    • Nifty Pharma emerges as top sectoral gainer; US generics players could benefit from Trump's tariffs

      Any tariffs on India or potential onshoring in US would be counterproductive, increasing the prices for US generics created by Indian pharma players.

    • Pharma stocks buck weak market; Dr Reddy's Labs, Cipla, Lupin up 1-4%

      Broad-based gains across most pharmaceutical stocks propelled the Nifty Pharma index over 1 percent higher, making it the sole sectoral gainer in today's trade.

    • Nifty Pharma climbs to all-time high; rises 10% in past one month

      Several market experts are seeing a case for strong buying within the pharma sectors, especially midcap names, driven by their comfortable valuations, decent earnings trajectory and robust growth prospects.

    • Market tanks but Dow Trend scanner indicates strength in these stocks; Check if you own any

      Nifty Pharma index made life highs while Nifty IT index is 1,000 points away from its life highs. The rally in defensive stocks indicates risk-off mood in the markets.

    • Budget to budget: Realty and PSU stocks shine; here's how various sectoral indices fared

      The rally in PSU stocks is attributed to the success of the Atmanirbhar Bharat initiative and the Make in India program, yielding positive results for most listed PSU companies.

    • Pharma stocks rally up to 8% to 52-week highs amid rise in fresh Covid cases

      The pharma industry is one of the few defensive industries and investor interest in it is also rising, as concerns about COVID-19 gain momentum, said Aamar Deo Singh, Senior Vice President, Research, Angel One.

    • Sensex, Nifty rally break amid profit-booking, defensive plays the favourite

      Nifty Pharma was the top sectoral performer followed by media and consumer durables

    • Sun Pharma market cap breezes past Rs 3 lakh crore, stock hits 52-week high

      So far this year, Sun Pharma shares surged over 26 percent as against 17 percent rise in the benchmark Sensex

    • Nifty Pharma scales record highs, rises in 14 out of 17 straight sessions

      In the second quarter of FY24, the Pharma stocks saw strong revenue growth of 14.3% year-over-year and 1.7% quarter-over-quarter

    • Strong pharma Q2 earnings lift Nifty Pharma index up 6% in seven straight sessions

      Q2 earnings of most drugmakers topped the Street's expectations despite modest growth in acute sales within the domestic pharma market.

    • Mixed day for pharma; Ipca Labs soars 7%, Laurus Labs tanks 10%

      The pharma sector has had a stellar run this year, so far, which also gives investors more leeway to take partial profits home

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347